Lenabasum (ajulemic acid)

Lenabasum (ajulemic acid, CT-3, IP-751, JBT-101, anabasum) is a synthetic, orally active, non-psychoactive cannabinoid that preferentially binds and activates the cannabinoid receptor type 2 (CB2) with approximately 12-fold selectivity over the cannabinoid receptor type 1 (CB1). The compound was designed by Sumner Burstein at the University of Massachusetts Medical School as a structural analog of delta-8-tetrahydrocannabinol-11-oic acid (delta-8-THC-11-oic acid), the terminal acid metabolite of delta-8-THC, in which the naturally occurring pentyl side chain is replaced by a 1,1-dimethylheptyl substituent to increase potency at the CB2 receptor while preserving the absence of centrally mediated psychoactive effects. The binding profile of ultrapure lenabasum has been characterized at Ki values of approximately 51 nM for CB2 and 628 nM for CB1, confirming peripheral immune-cell-directed pharmacology with minimal engagement of the central cannabinoid system responsible for the psychoactive effects of delta-9-tetrahydrocannabinol [1, 2].

The mechanism of action is distinct from conventional anti-inflammatory agents. CB2 receptor activation by lenabasum initiates the release of free arachidonic acid through phospholipase A2 stimulation, which is then metabolized through two convergent eicosanoid pathways: a cyclooxygenase-2-mediated pathway that produces the cyclopentenone prostaglandin 15-deoxy-delta-12,14-prostaglandin J2 (15d-PGJ2), a potent endogenous activator of peroxisome proliferator-activated receptor gamma (PPAR-gamma); and a lipoxygenase-mediated pathway that produces lipoxin A4 (LXA4), a specialized pro-resolving mediator [3, 4]. The downstream consequences include PPAR-gamma-dependent suppression of fibrogenesis, NF-kappaB-mediated proinflammatory cytokine reduction, and induction of apoptosis in activated T lymphocytes, collectively producing inflammation resolution without immunosuppression. The compound does not cross the blood-brain barrier efficiently, consistent with its lack of psychoactive effects at doses up to 80 mg daily in human clinical trials [5, 6].

Pharmacokinetics are characterized by rapid oral absorption, an elimination half-life of approximately 3 hours in healthy volunteers, high plasma protein binding (greater than 97 percent), and minimal hepatic metabolism with less than 5 percent of the parent compound converted to metabolites in human hepatocyte incubations [7, 8]. Physiologically based pharmacokinetic modeling predicts that lenabasum clearance is mediated predominantly by CYP2C9 (51 percent), CYP2C8 (37 percent), and CYP3A4 (12 percent), and the compound does not significantly inhibit the major CYP isoforms at concentrations up to 50 micromolar [8]. The safety profile is favorable: lenabasum is non-ulcerogenic at acute doses up to 1000 mg/kg in rodents, produces no physical dependence in 14-day rat studies, is negative on three standard mutagenicity assays, and has a therapeutic index exceeding 300-fold, substantially higher than conventional nonsteroidal anti-inflammatory drugs [9, 10].

Clinical development by Corbus Pharmaceuticals advanced lenabasum through Phase 2 trials demonstrating safety, tolerability, and preliminary efficacy signals in diffuse cutaneous systemic sclerosis (71 percent median improvement on the Combined Response Index), dermatomyositis (significant improvement on the Cutaneous Dermatomyositis Disease Area and Severity Index, P = 0.04), cystic fibrosis (dose-related reduction in pulmonary exacerbations in the CF-001 trial), and chronic neuropathic pain (significant pain reduction on the visual analog scale at 40 to 80 mg daily in the Karst et al. randomized controlled trial) [5, 11, 12, 13, 14]. However, both Phase 3 registration programs failed to meet their primary endpoints: the RESOLVE-1 trial in 365 systemic sclerosis patients (September 2020) and the DETERMINE trial in 176 dermatomyositis patients (June 2021) showed no significant separation from placebo on the primary efficacy measures [15, 16]. Development has since been discontinued by Corbus Pharmaceuticals. The compound remains available as a research-grade preparation and holds orphan drug designations from the FDA and EMA for systemic sclerosis, dermatomyositis, cystic fibrosis, and systemic lupus erythematosus. This monograph reviews the chemistry, synthesis, CB2 receptor pharmacology and downstream eicosanoid mechanisms, pharmacokinetics, the complete preclinical and clinical evidence base, safety profile, sourcing considerations, and a comparative assessment of five CB2-directed cannabinoid candidates against lenabasum on five competency standards.